BRAF mutation (any)

Any BRAF mutation (V600 and non-V600 classes) detected by sequencing; used as a predictive and, in some settings, prognostic marker.

CI-BIO-00000019BRAF graph →NCIt C40430 Tumor-agnostic · 4 approval rows

Also calledBRAF-mutant · BRAF-mutated · non-V600 BRAF · class II/III BRAF

Tissue-agnostic indications

Approval rows flagged tumor-agnostic (4)

Dabrafenib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Dabrafenib US FDA · May 29, 2013 · drug in derived setRegulatory approved
Trametinib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Trametinib US FDA · May 29, 2013 · drug in derived setRegulatory approved

The flag is the source's (openFDA label text), never inferred; the full indication text of each row is in the Approvals section below.

Derived

Associated cancers (32)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Melanoma	75	72	2	1	3 / 40 / 14 / 18 / 0
Malignant Colorectal Neoplasm	67	54	13	—	1 / 43 / 10 / 12 / 1
Cutaneous Melanoma	22	22	—	—

Derived

Drugs with predictive evidence (43)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
VemurafenibSmall Molecule	92	72	20	A	55 / 22	Childhood Pilocytic Astrocytoma, Cholangiocarcinoma, Cutaneous Melanoma, Digestive System Neuroendocrine Tumor +16
TrametinibSmall Molecule	53	51	2	A	50 / 2	Childhood Low Grade Glioma, Childhood Pilocytic Astrocytoma, Cholangiocarcinoma, Cutaneous Melanoma +13
DabrafenibSmall Molecule	40	33	7	A	34 / 11	Cholangiocarcinoma, Cutaneous Melanoma, Digestive System Neuroendocrine Tumor, Ganglioglioma +9
CetuximabMonoclonal Antibody	24	11	13	A	9 / 10	Malignant Colorectal Neoplasm, Solid Neoplasm
PanitumumabMonoclonal Antibody	14	8	6	B	5 / 4	Cholangiocarcinoma, Malignant Colorectal Neoplasm
IrinotecanSmall Molecule	12	5	7	B	5 / 6	Cholangiocarcinoma, Malignant Colorectal Neoplasm
SorafenibSmall Molecule	10	9	1	C	9 / 1	Childhood Pilocytic Astrocytoma, Cutaneous Melanoma, Malignant Colorectal Neoplasm, Melanoma +1
CobimetinibSmall Molecule	7	7	—	A	8 / 0	Malignant Colorectal Neoplasm, Malignant Neoplasm, Melanoma
EncorafenibSmall Molecule	6	6	—	A	6 / 0	Malignant Colorectal Neoplasm, Melanoma
Mitogen-Activated Protein Kinase Kinase Inhibitor	6	6	—	B	5 / 0	Cutaneous Melanoma, Melanoma
BevacizumabMonoclonal Antibody	5	3	2	B	3 / 2	Malignant Colorectal Neoplasm, Spindle Cell Sarcoma
BRAF Inhibitor	5	5	—	B	4 / 0	Melanoma
SelumetinibSmall Molecule	5	4	1	B	2 / 2	Childhood Pilocytic Astrocytoma, Malignant Colorectal Neoplasm, Malignant Neoplasm, Melanoma
OxaliplatinSmall Molecule	4	—	4	B	0 / 4	Malignant Colorectal Neoplasm
BinimetinibSmall Molecule	3	3	—	A	3 / 0	Malignant Colorectal Neoplasm, Melanoma
TovorafenibSmall Molecule	2	2	—	A	4 / 0	Childhood Low Grade Glioma
CapecitabineSmall Molecule	2	1	1	B	1 / 1	Malignant Colorectal Neoplasm
DactolisibSmall Molecule	2	2	—	D	2 / 0	Malignant Colorectal Neoplasm, Melanoma
PLX4720	2	2	—	D	2 / 0	Malignant Colorectal Neoplasm, Melanoma
TemsirolimusSmall Molecule	2	2	—	C	2 / 0	Spindle Cell Sarcoma
U0126	2	—	2	D	0 / 2	Cutaneous Melanoma
UprosertibSmall Molecule	2	2	—	D	2 / 0	Melanoma
Regorafenib AnhydrousSmall Molecule	2	1	1	C	0 / 1	Gastrointestinal Stromal Tumor
MEK Inhibitor RO4987655	2	—	2	B	—	Melanoma
AlpelisibSmall Molecule	1	1	—	B	1 / 0	Malignant Colorectal Neoplasm
AtezolizumabMonoclonal Antibody	1	1	—	A	1 / 0	Melanoma
BelvarafenibSmall Molecule	1	1	—	C	1 / 0	Melanoma
Chemotherapy	1	—	1	B	0 / 1	Malignant Colorectal Neoplasm
Dabrafenib/Trametinib Regimen	1	1	—	C	1 / 0	Histiocytic Sarcoma
ErlotinibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
EverolimusSmall Molecule	1	1	—	D	1 / 0	Childhood Low Grade Glioma
FOLFOX-4 Regimen	1	—	1	B	0 / 1	Malignant Colorectal Neoplasm
GDC-0879Small Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
GefitinibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
JQEZ5	1	1	—	D	1 / 0	Melanoma
MEK Inhibitor REC-4881	1	1	—	C	1 / 0	Cutaneous Melanoma
Nutlin-3Small Molecule	1	1	—	D	1 / 0	Melanoma
Pan-RAF Inhibitor LY3009120Small Molecule	1	1	—	D	1 / 0	Malignant Neoplasm
PertuzumabMonoclonal Antibody	1	1	—	C	1 / 0	Thyroid Gland Anaplastic Carcinoma
PictilisibSmall Molecule	1	1	—	C	1 / 0	Melanoma
Pictilisib Bismesylate	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
RefametinibSmall Molecule	1	—	1	C	0 / 1	Melanoma
MirdametinibSmall Molecule	1	—	1	D	—	Melanoma

Curatedcivic items and knowledge edges as curated at the source.

Curated evidence

Predictive evidence items (214)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 1–50 of 214 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BRAF V600E + BRAF Fusion1
Tovorafenib	Childhood Low Grade Glioma	Predictive	A	Supports Sensitivity Response	5	accepted	EID12016 In this ongoing phase 2 trial (FIREFLY-1), 76 patients, aged 6 months to 25 years, with pediatric low-grade glioma harbouring BRAF alterations (BRAF fusions or BRAF V600E mutations) were treated with … (full text at CIViC) PMID 37978284 · Kilburn et al., 2024 · Open in CIViC	civic
BRAF V600 + BRAF Fusion1
Tovorafenib	Childhood Low Grade Glioma	Predictive	A	Supports Sensitivity Response	5	accepted	EID12028 In this phase 2 clinical trial, the efficacy of RAF inhibitor tovorafenib (DAY-101) was investigated in patients between the ages of 6 months and 25 years, with pediatric low-grade gliomas harbouring … (full text at CIViC) PMID 37978284 · Kilburn et al., 2024 · Open in CIViC	civic
BRAF Fusion5
Everolimus + TrametinibCombination	Childhood Low Grade Glioma	Predictive	D	Supports Sensitivity Response	2	accepted	EID7199 This preclinical study proposed to use a combination therapy of an MEK inhibitor (e.g. trametinib) and an mTOR inhibitor (e.g. everolimus) for the treatment of pediatric low-grade gliomas (PLGGs) with… (full text at CIViC) PMID 29156677 · Jain et al., 2017 · Open in CIViC	civic
Selumetinib	Childhood Pilocytic Astrocytoma	Predictive	D	Supports Sensitivity Response	2	accepted	EID8943 In this preclinical experiment, a pediatric pilocytic astrocytoma cell line (DKFZ-BT66) harboring KIAA1549:BRAF fusion was generated from a two year old patient. Treatment with selumetinib resulted in… (full text at CIViC) PMID 28002790 · Selt et al., 2017 · Open in CIViC	civic
Sorafenib + VemurafenibSubstitutes	Childhood Pilocytic Astrocytoma
BRAF V600E16
Vemurafenib	Childhood Pilocytic Astrocytoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID3777 In a case report, a 28 month old patient with a cervicomedullary low grade glioma compatible with pilocytic astrocytoma which was resected had a second lesion consistent with a ganglioglioma 3 years l… (full text at CIViC) PMID 25524464 · del Bufalo et al., 2014 · Open in CIViC	civic
Dabrafenib + TrametinibCombination	Cholangiocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID5902 Chemotherapy-refractory, metastatic cholangiocarcinoma with CNS involvement and a BRAF V600E mutation had a partial response at 8 weeks to dabrafenib and trametinib combination with complete radiologi… (full text at CIViC) PMID 28480077 · Kocsis et al., 2017 · Open in CIViC	civic
Irinotecan + Panitumumab + VemurafenibCombination	Cholangiocarcinoma
BRAF V6005
Vemurafenib	Cholangiocarcinoma	Predictive	B	Supports Sensitivity Response	4	accepted	EID5905 Eight patients with BRAF V600 (7 with V600E, 1 with V600 unknown) mutated cholangiocarcinoma received vemurafenib. Only one patients showed partial response and duration of response of this patient wa… (full text at CIViC) PMID 26287849 · Hyman et al., 2015 · Open in CIViC	civic
Dabrafenib + TrametinibCombination	Cutaneous MelanomaALIAS	Predictive	A	Supports Sensitivity Response	5	accepted	EID1411 The Combi-v (NCT01597908) open-label, randomized phase 3 trial had 704 patients with metastatic melanoma with a BRAF V600 mutation. Patients were randomized to receive either a combination of dabrafen… (full text at CIViC) PMID 25399551 · Robert et al., 2015 · Open in CIViC	civic
Dabrafenib/Trametinib Regimen	Histiocytic Sarcoma
BRAF L597S2
MEK Inhibitor REC-4881	Cutaneous MelanomaALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID1460 Case report of a 69 year old patient with metastatic melanoma treated with MEK inhibitor TAK-733 in a clinical trial. A partial radiographic response with a decrease of 31% in the sum of maximum diame… (full text at CIViC) PMID 22798288 · Dahlman et al., 2012 · Open in CIViC	civic
Trametinib + VemurafenibSubstitutes	Cutaneous MelanomaALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID1459 Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutant–expressing cells led… (full text at CIViC) PMID 22798288 · Dahlman et al., 2012 · Open in CIViC	civic
BRAF D594G2
Sorafenib	Cutaneous MelanomaALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID6001 In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition but underwent apoptosis after shRN… (full text at CIViC) PMID 18794803 · Smalley et al., 2009 · Open in CIViC	civic
U0126	Cutaneous MelanomaALIAS	Predictive	D	Supports Resistance	3	accepted	EID6002 In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition but underwent apoptosis after shRN… (full text at CIViC) PMID 18794803 · Smalley et al., 2009 · Open in CIViC	civic
BRAF G469E2
Sorafenib	Cutaneous MelanomaALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID6003 In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition but underwent apoptosis after shRN… (full text at CIViC) PMID 18794803 · Smalley et al., 2009 · Open in CIViC	civic
U0126	Cutaneous MelanomaALIAS	Predictive	D	Supports Resistance	3	accepted	EID6004 In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition (U0126) but underwent apoptosis af… (full text at CIViC) PMID 18794803 · Smalley et al., 2009 · Open in CIViC	civic
BRAF D594A1
Mitogen-Activated Protein Kinase Kinase Inhibitor + SorafenibSubstitutes	Cutaneous MelanomaALIAS	Predictive	E	Supports Sensitivity Response	3	accepted	EID1454 Preclinical study in melanoma cell lines. Inactivity of BRAF as mediated by specific mutation (D594A, D594V or K483M) or selective pharmacological inhibition leads to MEK hyperactivation through CRAF … (full text at CIViC) PMID 20141835 · Heidorn et al., 2010 · Open in CIViC	civic
BRAF K483M1
Mitogen-Activated Protein Kinase Kinase Inhibitor + SorafenibSubstitutes	Cutaneous MelanomaALIAS	Predictive	E	Supports Sensitivity Response	3	accepted	EID1457 Preclinical study in melanoma cell lines. Inactivity of BRAF as mediated by specific mutation (D594A, D594V or K483M) or selective pharmacological inhibition leads to MEK hyperactivation through CRAF … (full text at CIViC) PMID 20141835 · Heidorn et al., 2010 · Open in CIViC	civic
BRAF D594V1
Sorafenib + TrametinibSubstitutes	Cutaneous MelanomaALIAS	Predictive	E	Supports Sensitivity Response	3	accepted	EID1456 Preclinical study in melanoma cell lines. Inactivity of BRAF as mediated by specific mutation (D594A, D594V or K483M) or selective pharmacological inhibition leads to MEK hyperactivation through CRAF … (full text at CIViC) PMID 20141835 · Heidorn et al., 2010 · Open in CIViC	civic
BRAF L597V1
Trametinib	Cutaneous MelanomaALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID1463 Case report of a phase 1 study in advanced melanoma patients. 97 patients with melanoma were enrolled and treated with trametinib. One patient with a BRAF Leu597Val had a confirmed partial response wi… (full text at CIViC) PMID 22805292 · Falchook et al., 2012 · Open in CIViC	civic
BRAF Fusion1
Trametinib	Cutaneous MelanomaALIAS	Predictive	C	Supports Sensitivity Response	2	accepted	EID1570 Case report of a 47year old female patient with metastatic melanoma (BRAF, NRAS, KIT negative). A PPFIBP2-BRAF fusion was identified from DNA from a brain metastasis (inton 3 of PPFIBP2 fused to intro… (full text at CIViC) PMID 26072686 · Menzies et al., 2015 · Open in CIViC	civic
BRAF L597Q2
Trametinib	Cutaneous MelanomaALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID4905 Case study report including one patient with L597Q mutation-positive metastatic melanoma (M1b disease) treated with the MEK inhibitor trametinib. The L597Q patient achieved a RECIST partial response a… (full text at CIViC) PMID 24933606 · Bowyer et al., 2014 · Open in CIViC	civic
Trametinib + VemurafenibSubstitutes	Cutaneous MelanomaALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID1461 Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutant–expressing cells led… (full text at CIViC) PMID 22798288 · Dahlman et al., 2012 · Open in CIViC	civic
BRAF Fusion1
Trametinib	Cutaneous MelanomaALIAS	Predictive	C	Supports Sensitivity Response	2	accepted	EID13150 A 42 year old male patient with stage III cutaneous melanoma harboring an AGAP3::BRAF fusion was treated with the MEK inhibitor trametinib after prior pembrolizumab and experienced a response lasting … (full text at CIViC) PMID 35871080 · Moran et al., 2022 · Open in CIViC	civic
BRAF V600K1
Dabrafenib + TrametinibCombination	Cutaneous MelanomaALIAS	Predictive	B	Supports Sensitivity Response	3	accepted	EID4181 In a phase 3 clinical trial (NCT01597908) involving 704 patients with metastatic melanoma harboring BRAF V600 mutations, a subgroup analysis of patients with V600K mutations showed an objective respon… (full text at CIViC) PMID 25399551 · Robert et al., 2015 · Open in CIViC	civic
BRAF Fusion1
Vemurafenib	Cutaneous MelanomaALIAS	Predictive	D	Supports Resistance	3	accepted	EID1416 Foundation One NGS assay and targeted RNAseq identified PAPSS1-BRAF fusion in a melanoma sample. Further BRAF fusions (TRIM24-BRAF) were identified in TCGA and additional samples. Ectopic expression o… (full text at CIViC) PMID 24345920 · Hutchinson et al., 2013 · Open in CIViC	civic
BRAF L597R1
Trametinib + VemurafenibSubstitutes	Cutaneous MelanomaALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID1458 Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutant–expressing cells led… (full text at CIViC) PMID 22798288 · Dahlman et al., 2012 · Open in CIViC	civic
BRAF K601E1
Trametinib + VemurafenibSubstitutes	Cutaneous MelanomaALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID1462 Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutant–expressing cells led… (full text at CIViC) PMID 22798288 · Dahlman et al., 2012 · Open in CIViC	civic
BRAF T599dup1
Dabrafenib + TrametinibCombination	Ganglioglioma	Predictive	C	Supports Sensitivity Response	3	accepted	EID9789 A pediatric case of ganglioglioma was previously reported (PMID: 29434027) to harbor a BRAF p.T599dup variant (observed at VAF of 5.2%). The patient had a partial resection and was then treated with V… (full text at CIViC) PMID 33637608 · Miller et al., 2021 · Open in CIViC	civic
BRAF Exon 15 Mutation2
Regorafenib Anhydrous	Gastrointestinal Stromal Tumor	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID4121 This phase II clinical trial of regorafenib (NCT01068769) examined the long term safety and efficacy of regorafenib monotherapy in patients with metastatic and/or unresectable gastrointestinal stromal… (full text at CIViC) PMID 27371698 · Ben-Ami et al., 2016 · Open in CIViC	civic
〃	Gastrointestinal Stromal Tumor	Predictive	C	Supports Resistance	1	accepted	EID4605 This retrospective study of a phase 2 clinical trial (NCT01068769) examined regorafenib safety and efficacy in advanced gastrointestinal stromal tumor (GIST) patients refractory to at least imatinib a… (full text at CIViC) PMID 22614970 · George et al., 2012 · Open in CIViC	civic
BRAF G596C1
Dabrafenib + TrametinibCombination	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	2	accepted	EID1738 Non-V600 BRAF mutations occur in about half of BRAF-mutated lung cancers, and their sensitivity to Dabrafenib and Trametinib is not well documented. In a cohort of 229 NSCLC patients that underwent mo… (full text at CIViC) PMID 28947956 · Noeparast et al., 2017 · Open in CIViC	civic

Regulatory

Approvals mentioning the linked drugs (458)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

openfdaRegulatory50 approval records from 3 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Capecitabine	US FDA	—	Efficacy supplement 2022-12-14 (see label)	approved	Dec 14, 2022	openfda
Capecitabine	US FDA	—	Efficacy supplement 2022-12-14 (see label)	approved	Dec 14, 2022	openfda
Capecitabine	US FDA	—	Efficacy supplement 2022-12-14 (see label)	approved	Dec 14, 2022	openfda
Capecitabine	US FDA	—	Efficacy supplement 2022-12-14 (see label)	approved	Dec 14, 2022

Health Canada DIN rows carry no indication text and only match by drug.

Clinical trials

Active trials (629)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 333 recruiting · 118 active phase 3 · 2,987 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 601–629 of 629 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03767075	A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)(BoB)	recruiting	Phase 2	1,000	Vall d'Hebron Institute of OncologyOTHER	7	Apr 25, 2024	clinicaltrials
NCT06373133	SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer	not yet recruiting	Phase 1 / Phase 2	36	West China HospitalOTHER	0	Apr 18, 2024	clinicaltrials
NCT06259058	Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer	not yet recruiting	Phase 1 / Phase 2	96	Tianjin Medical University Cancer Institute and HospitalOTHER	0	Mar 15, 2024	clinicaltrials
NCT06307249	Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA(PTST_PALBEVA)	recruiting	Phase 1	50	Lebanese UniversityOTHER	1	Mar 12, 2024	clinicaltrials
NCT05007132	Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer	recruiting	Phase 2	153	Dominik Paul ModestOTHER	1	Feb 15, 2024	clinicaltrials
NCT03494946	Liver Transplantation Compared to Chemotherapy in Patients With ColoRectal Cancer(SECAIII)	recruiting	N/A	30	Oslo University HospitalOTHER	1	Feb 6, 2024	clinicaltrials
NCT02925234	The Drug Rediscovery Protocol (DRUP Trial)(DRUP)	recruiting	Phase 2	1,550	The Netherlands Cancer InstituteOTHER	1	Jan 24, 2024	clinicaltrials
NCT06192680	Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer	not yet recruiting	Phase 2	63	Harbin Medical UniversityOTHER	0	Jan 18, 2024	clinicaltrials
NCT06210360	Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX	not yet recruiting	Phase 2	134	Changhai HospitalOTHER	0	Jan 18, 2024	clinicaltrials
NCT06159478	Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)(Perfume)	recruiting	Phase 2	32	National Cancer Center, JapanOTHER_GOV	1	Dec 13, 2023	clinicaltrials
NCT06121700	Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer(Miracle-G)	recruiting	Phase 2	55	Fudan UniversityOTHER	1	Nov 8, 2023	clinicaltrials
NCT06102837	Tumor Vaccines for Solid Tumors	recruiting	—	340	Huashan HospitalOTHER	1	Oct 26, 2023	clinicaltrials
NCT06079333	NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)(NEO-ATACT)	recruiting	Phase 2	20	Leiden University Medical CenterOTHER	1	Oct 12, 2023	clinicaltrials
NCT06067776	Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer	not yet recruiting	Phase 1	36	Jonathan RiessOTHER	1	Oct 5, 2023	clinicaltrials
NCT06063070	First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer	not yet recruiting	Phase 2	44	Sun Yat-sen UniversityOTHER	1	Oct 2, 2023	clinicaltrials
NCT04728724	Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer	recruiting	Phase 2	100	Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER	1	Sep 13, 2023	clinicaltrials
NCT03563729	Melanoma Metastasized to the Brain and Steroids(MEMBRAINS)	recruiting	Phase 2	80	Inge Marie SvaneOTHER	1	Jul 13, 2023	clinicaltrials
NCT05354674	Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis	not yet recruiting	—	302	Fudan UniversityOTHER	1	Jul 13, 2023	clinicaltrials
NCT05797467	Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients	recruiting	Phase 3	366	Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER	1	May 24, 2023	clinicaltrials
NCT05797077	Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA	recruiting	Phase 3	346	Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER	1	Apr 4, 2023	clinicaltrials
NCT05725200	Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer(EVIDENT)	recruiting	Phase 2	40	Oslo University HospitalOTHER	1	Feb 21, 2023	clinicaltrials
NCT04304209	Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer	active not recruiting	Phase 2	195	Sun Yat-sen UniversityOTHER	1	Feb 1, 2023	clinicaltrials
NCT05699746	CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD	not yet recruiting	Phase 3	38	Zhejiang UniversityOTHER	1	Jan 26, 2023	clinicaltrials
NCT05607329	Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial	recruiting	N/A	400	Women's Hospital School Of Medicine Zhejiang UniversityOTHER	1	Nov 7, 2022	clinicaltrials
NCT05429515	Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury	not yet recruiting	Phase 4	50	Peking Union Medical College HospitalOTHER	0	Jun 23, 2022	clinicaltrials
NCT05186506	A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer	not yet recruiting	Phase 2	152	Sichuan UniversityOTHER	0	Jan 11, 2022	clinicaltrials
NCT01638676	A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients	recruiting	Phase 1 / Phase 2	55	University of LouisvilleOTHER	1	Oct 29, 2021	clinicaltrials
NCT04045691	Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment(BERING)	recruiting	—	750	Pierre Fabre Pharma GmbHINDUSTRY	3	Jan 19, 2021	clinicaltrials
NCT02446431	Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence(Metronomic)	recruiting	Early Phase 1	20	Miller Children's & Women's Hospital Long BeachOTHER	1	May 18, 2015	clinicaltrials

A study listed here tests a linked drug in a linked cancer; it does not necessarily select participants on this biomarker.

Approval rows flagged tumor-agnostic (4)

Associated cancers (32)

Drugs with predictive evidence (43)

Predictive evidence items (214)

Approvals mentioning the linked drugs (458)

Active trials (629)

Linked publications (142)